Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Raw Materials (2020 - 2025)

Historic Raw Materials for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to $21.9 million.

  • Bioventus' Raw Materials fell 663.17% to $21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.9 million, marking a year-over-year decrease of 663.17%. This contributed to the annual value of $22.1 million for FY2024, which is 491.88% up from last year.
  • Per Bioventus' latest filing, its Raw Materials stood at $21.9 million for Q3 2025, which was down 663.17% from $23.4 million recorded in Q2 2025.
  • Bioventus' 5-year Raw Materials high stood at $26.4 million for Q3 2023, and its period low was $3.4 million during Q4 2021.
  • For the 5-year period, Bioventus' Raw Materials averaged around $18.7 million, with its median value being $21.9 million (2025).
  • As far as peak fluctuations go, Bioventus' Raw Materials soared by 41404.91% in 2022, and later crashed by 1123.26% in 2024.
  • Over the past 5 years, Bioventus' Raw Materials (Quarter) stood at $12.2 million in 2021, then surged by 51.1% to $18.5 million in 2022, then rose by 14.13% to $21.1 million in 2023, then rose by 4.92% to $22.1 million in 2024, then dropped by 0.86% to $21.9 million in 2025.
  • Its Raw Materials was $21.9 million in Q3 2025, compared to $23.4 million in Q2 2025 and $22.8 million in Q1 2025.